Literature DB >> 24080745

Myoglobin removal using high-volume high-flux hemofiltration in patients with oliguric acute kidney injury.

Nelio Guzman1, Amber S Podoll, Cynthia S Bell, Kevin W Finkel.   

Abstract

BACKGROUND: Rhabdomyolysis can cause acute kidney injury (AKI). It remains controversial whether or not myoglobin can be removed from the circulation with extracorporeal therapy and decrease the incidence of AKI. Therefore, we examined myoglobin removal in a series of 11 patients with oliguric AKI treated with high-volume hemofiltration.
METHODS: Patients received prefilter hemofiltration using a polysulphone filter with a molecular size cutoff of 65 kDa and a surface area of 1.7 m(2). Sieving coefficients and myoglobin clearances were calculated at 6, 12, and 24 h after the start of hemofiltration.
RESULTS: The mean sieving coefficient was 0.158, and the mean myoglobin clearance was 8.7 ml/min.
CONCLUSION: Despite the use of high-volume hemofiltration, the removal of myoglobin was negligible. In patients with normal renal function, the anticipated amount of extracorporeal removal would not significantly impact renal exposure to myoglobin.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080745     DOI: 10.1159/000354727

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  2 in total

1.  Early application of continuous high-volume haemofiltration can reduce sepsis and improve the prognosis of patients with severe burns.

Authors:  Bo You; Yu Long Zhang; Gao Xing Luo; Yong Ming Dang; Bei Jiang; Guang Tao Huang; Xin Zhu Liu; Zi Chen Yang; Yu Chen; Jing Chen; Zhi Qiang Yuan; Su Peng Yin; Yi Zhi Peng
Journal:  Crit Care       Date:  2018-07-06       Impact factor: 9.097

Review 2.  Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19.

Authors:  Ewelina Młynarska; Julia Krzemińska; Magdalena Wronka; Beata Franczyk; Jacek Rysz
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.